Invivyd (IVVD) Hisse Özeti

Bir biyofarmasötik şirketi olan Invivyd, Inc. Amerika Birleşik Devletleri'nde bulaşıcı hastalıklar için antikor bazlı çözümlerin keşfi, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Daha fazla detay

IVVD temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 98.5% daha düşük bir oranda işlem görüyor

Gelirin yılda 39.7% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 11.3% oranında arttı

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Son 3 ayda hisse senedi fiyatı US piyasasına kıyasla oldukça dalgalı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

IVVD Community Fair Values

Create Narrative

See what 83 others think this stock is worth. Follow their fair value or set your own to get alerts.

Invivyd

AnalystConsensusTarget

Based on Analyst Price Targets

Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update

Key Takeaways Expansion of a skilled commercial team and new therapeutic programs positions Invivyd for broader market adoption, revenue growth, and reduced product concentration risk. Financial discipline and evolving regulatory support enhance sustainability, lower risk, and may fast-track product approvals and recurring revenue opportunities.

View narrative

US$10

84.4% değerinin altında

68.74%

Revenue growth p.a.

531

Invivyd

AnalystLowTarget

Community Contributor

Regulatory Risks And Competition Will Impede Gains But Yield Promise

Key Takeaways Heavy reliance on emergency authorizations, regulatory uncertainties, and a narrow late-stage pipeline threaten Invivyd's long-term revenue stability and growth prospects. Heightened pricing pressures, high R&D costs, and formidable competition may erode profitability despite strong product demand and innovative advances in antibody engineering.

View narrative

US$1

56.0% aşırı değerlenmiş

95.47%

Revenue growth p.a.

Invivyd

AnalystHighTarget

Community Contributor

Rapid Antibody Advances Will Leverage Secular Pandemic Trends

Key Takeaways Invivyd's COVID-19 and next-generation antibody products are primed for durable, expanding revenue streams, potentially outpacing market expectations through breakthrough clinical benefits and guideline inclusion. The company's diversified pipeline, pandemic readiness focus, and operational efficiency position it for higher growth, stronger margins, and sustained earnings in a shifting healthcare landscape.

View narrative

US$5

68.8% değerinin altında

112.11%

Revenue growth p.a.

View Stock Community

Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

1.4k

US$21.53

71.2% değerinin altında

stuart_roberts's Fair Value

Profit Margin

20%

Future PE

27x

Price in 2030

US$34.67

Invivyd, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Invivyd
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.56
52 Haftanın En Yüksek Seviyesi	US$3.07
52 Haftanın En Düşük Seviyesi	US$0.46
Beta	0.60
1 Aylık Değişim	-40.00%
3 Aylık Değişim	-33.62%
1 Yıllık Değişim	-3.11%
3 Yıllık Değişim	-20.00%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-92.53%

Son Haberler & Güncellemeler

Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk

Jan 29

Recent updates

Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk

Jan 29

Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking

Nov 29

Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination

Nov 18

Invivyd, Inc.'s (NASDAQ:IVVD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Oct 14

Why Investors Shouldn't Be Surprised By Invivyd, Inc.'s (NASDAQ:IVVD) 31% Share Price Plunge

Aug 22

Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025

Apr 23 The development of next-generation antibodies could expand market reach and improve margins by lowering production and administration costs.

I See The Bull Case For Invivyd, But I'm Not Married To It

Feb 04

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Feb 01

Here's Why We're Watching Invivyd's (NASDAQ:IVVD) Cash Burn Situation

Jul 16

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

Mar 29

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Oct 24

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Jul 04

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Mar 19

Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

Nov 19

Invivyd appoints interim CFO, makes headcount changes

Oct 13

Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies

Sep 12

Adagio Therapeutics GAAP EPS of -$0.47

Aug 15

Hissedar Getirileri

	IVVD	US Biotechs	US Pazar
7D	-1.9%	-1.2%	-1.4%
1Y	-3.1%	27.8%	10.9%

Getiri vs. Endüstri: IVVD geçen yıl % 27.8 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: IVVD geçen yıl % 10.9 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is IVVD's price volatile compared to industry and market?
IVVD volatility
IVVD Average Weekly Movement	17.3%
Biotechs Industry Average Movement	10.7%
Market Average Movement	6.4%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: IVVD hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: IVVD 'nin haftalık oynaklığı ( 17% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2020	100	Bill Duke	invivyd.com

Bir biyofarmasötik şirketi olan Invivyd, Inc, Amerika Birleşik Devletleri'nde bulaşıcı hastalıklar için antikor bazlı çözümlerin keşfi, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Şirketin boru hattı, yetişkinlerde ve ergenlerde COVID-19'un önlenmesi için yarı ömrü uzatılmış bir araştırma monoklonal antikoru (mAb) olan PEMGARDA (pemivibart) enjeksiyonunu; COVID-19'un önlenmesi veya tedavisi için klinik öncesi çalışmalarda bulunan bir mAb adayı olan VYD2311'i; ve COVID-19'un önlenmesi ve tedavisi için faz 2/3 klinik çalışmalarda bulunan Adintrevimab'ı içermektedir. Ayrıca mevsimsel influenza ve COVID-19'un önlenmesi için keşif aşamasında adayları bulunmaktadır.

Invivyd, Inc. Temel Bilgiler Özeti

Invivyd'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
IVVD temel i̇stati̇sti̇kler
Piyasa değeri	US$431.44m
Kazançlar(TTM)	-US$59.86m
Gelir(TTM)	US$50.04m

8.8x

P/S Oranı

-7.3x

F/K Oranı

IVVD aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
IVVD gelir tablosu (TTM)
Gelir	US$50.04m
Gelir Maliyeti	US$3.33m
Brüt Kâr	US$46.71m
Diğer Giderler	US$106.57m
Kazançlar	-US$59.86m

Son Raporlanan Kazançlar

Sep 30, 2025

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.21
Brüt Marj	93.34%
Net Kâr Marjı	-119.63%
Borç/Özkaynak Oranı	0%

IVVD uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/02/13 16:28
Gün Sonu Hisse Fiyatı	2026/02/13 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Invivyd, Inc. 6 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Thomas Shrader	BTIG
Joshua Schimmer	Cantor Fitzgerald & Co.
Jason Kolbert	D. Boral Capital LLC.

Invivyd (IVVD) Hisse Özeti

Ödüller

Risk Analizi

Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update

Regulatory Risks And Competition Will Impede Gains But Yield Promise

Rapid Antibody Advances Will Leverage Secular Pandemic Trends

Looking to be second time lucky with a game-changing new product

Invivyd, Inc. Rakipler

Keros Therapeutics

Kura Oncology

X4 Pharmaceuticals

Geron

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Invivyd Aligns with the U.S. Fda on Liberty, A Phase 3 Trial to Evaluate the Safety of Vyd2311 Antibody Versus Mrna Covid Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine

Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

Recent updates

Invivyd Aligns with the U.S. Fda on Liberty, A Phase 3 Trial to Evaluate the Safety of Vyd2311 Antibody Versus Mrna Covid Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine

Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking

Invivyd, Inc. Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329

Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination

Invivyd, Inc. has completed a Follow-on Equity Offering in the amount of $124.9994 million.

Invivyd, Inc.'s (NASDAQ:IVVD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Invivyd, Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application and Provide Feedback to Advance the Company's Revolation Clinical Program

Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

Invivyd, Inc. Appoints Kristie Kuhl as Chief Communications Officer

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At Recover-TLC Workshop

Invivyd, Inc. has completed a Follow-on Equity Offering in the amount of $49.997866 million.

Why Investors Shouldn't Be Surprised By Invivyd, Inc.'s (NASDAQ:IVVD) 31% Share Price Plunge

Invivyd, Inc. has filed a Follow-on Equity Offering.

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA®? (Pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG

Invivyd, Inc. Aligns with U.S. FDA on Rapid Pathway to Full Approval of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long Covid and Covid-19 Post-Vaccination Syndrome

Invivyd, Inc. Announces Positive Full Phase 1/2 Clinical Data for VYD2311, A Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Invivyd Announces Publication of Landmark CANOPY Phase 3 Pemivibart Clinical Trial

Invivyd, Inc. Announces Inclusion of PEMGARDA (Pemivibart) in National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd, Inc. Commends FDA Focus on Contemporary Evidence in Evaluating Medical Interventions to Prevent Covid-19

Invivyd, Inc. Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies for Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025

Invivyd, Inc., Annual General Meeting, May 20, 2025

Invivyd, Inc. Appoints Ajay Royan, to Its Board of Directors

Invivyd, Inc. Auditor Raises 'Going Concern' Doubt

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA™? (Pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

I See The Bull Case For Invivyd, But I'm Not Married To It

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Invivyd, Inc. Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Invivyd, Inc. Announces Resignation of Sara Cotter from the Board of Directors

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers

Invivyd, Inc. Withdraws Financial Guidance for the Year 2024

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda™ (Pemivibart) Provided Substantial Protection from Symptomatic Covid-19 Versus Placebo over Six Months of Follow-Up, with No Additional Doses, in Immunocompetent Participants

Invivyd, Inc. Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Sensibility and PEMGARDA Activity Data

Invivyd, Inc. Doses First Participants in Phase 1 Clinical Trial of VYD2311, A Next Generation Monoclonal Antibody Candidate for COVID-19

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

Here's Why We're Watching Invivyd's (NASDAQ:IVVD) Cash Burn Situation

Invivyd Announces General Alignment with U.S. FDA on A Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

Invivyd, Inc. Announces Management Changes

Invivyd, Inc. Elects Two New Independent Members to its Board of Directors

Forecast to breakeven in 2026

Invivyd, Inc. to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

Invivyd, Inc., Annual General Meeting, May 21, 2024

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda

Invivyd, Inc. Announces CEO Changes

New minor risk - Profitability

No longer forecast to breakeven

Consensus revenue estimates fall by 13%

Invivyd, Inc. Provides Earnings Guidance for the Year 2024

Forecast breakeven date moved forward to 2025

Consensus revenue estimates increase by 64%

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

New minor risk - Shareholder dilution

Forecast to breakeven in 2026